Delivery Order SPE2DB22D2206-SPE2DB25FJG17
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $19,253.01 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical supplies. The contract, executed on August 5, 2025, with an ultimate completion date of August 6, 2025, utilizes firm fixed pricing and represents a non-set-aside competitive award. Performance will be conducted at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a $48,698.09 delivery order to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical supplies. This firm fixed price, competitively awarded contract was executed on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework...
- The Defense Logistics Agency awarded a delivery order valued at $7,609.13 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL pharmaceutical product. This is a firm fixed price, competitively awarded contract with no set-aside designation, with an ultimate completion date of July 30, 2025. The award was made on July 29, 2025, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,863.20 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Actemra Actpen (162 mg/0.9 mL) pharmaceutical product. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract was awarded competitively with no set-aside designation. This delivery order is issued under AmerisourceBergen...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $7,966.67 by the Defense Logistics Agency (DLA) on August 15, 2025, with an ultimate completion date of August 18, 2025. The contract is for the supply of Actemra ActPen 162 mg/0.9 ml pharmaceutical product under firm fixed pricing with no set-aside designation. This delivery order is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at approximately $51,886 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen (162 mg/0.9 mL) pharmaceutical product, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract was issued on July 24, 2025, with performance to be completed at the contractor's facility in Conshohocken, Pennsylvania. The award includes no set-aside designation, reflecting open competition among...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,075.18 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 ml pharmaceutical product. This firm fixed-price delivery order was competitively awarded without set-aside designation and carries an ultimate completion date of September 19, 2025. The award represents a continuation of services under AmerisourceBergen's broader contract vehicle with DLA, leveraging the company's established...
- The Defense Logistics Agency awarded a delivery order valued at $15,757.28 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a delivery order valued at $5,718.32 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 6, 2025, with completion due by August 7, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJG17Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,967.40 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml pharmaceutical product on August 6, 2025, with an ultimate completion date of August 7, 2025. The contract is a firm fixed price delivery order with no set-aside designation, and performance will take place at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's larger prime indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor, serves as a critical vendor for federal medical procurement supporting military and veteran healthcare systems. The parent IDC vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. The company's contract awards with the Defense Logistics Agency demonstrate consistent capability to fulfill federal medical supply requirements through competitive procurement, with delivery orders typically structured as firm fixed price arrangements ranging from modest to substantial values.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 8/6/25 |